首页> 外文期刊>Oncology letters >Expression of miR-146a in patients with ovarian cancer and its clinical significance
【24h】

Expression of miR-146a in patients with ovarian cancer and its clinical significance

机译:miR-146a在卵巢癌患者中的表达及其临床意义

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of the present retrospective study was to compare microRNA (miR)-146a expression levels in primary tumors and omental metastases of 48 patients, who had undergone surgery for advanced ovarian serous cancer. Possible correlations between miR-146a expression level and clinicopathological features were investigated, including chemosensitivity and survival. miR-146a was evaluated in formalin-fixed, paraffin-embedded samples. miR-146a expression level in primary tumors was demonstrated to be increased in comparison with normal ovary tissues (P=0.02) and metastases (P=0.01). A negative correlation was demonstrated between miR-146a expression in primary tumors and serum levels of cancer antigen 125 (R=-.0.37; P=0.03) and Risk of Malignancy Algorithm index (R=-0.79; P=0.0007). Overall survival positively correlated with miR-146a expression in primary tumor tissue samples (R=0.38; P=0.01). Probability of survival was decreased in patients with low miR-146a expression levels in primary tumor tissues (hazard ratio=0.21; P=0.003). Lower levels of miR-146a in primary tumor tissue samples were correlated with a shorter progression-free survival (P=0.04) and platinum-resistance of metastases (P=0.006). In conclusion, miR-146a may be a prognostic marker for serous ovarian cancer.
机译:本回顾性研究的目的是将MicroRNA(miR)-146A表达水平与48名患者的原发性肿瘤和题转移进行比较,他们经历过晚期卵巢浆液癌手术。研究了miR-146a表达水平与临床病理学特征之间的可能相关性,包括化学敏感性和存活。在福尔马林固定的石蜡包埋的样品中评估miR-146a。与正常卵巢组织(P = 0.02)和转移(P = 0.01)相比,证明原发性肿瘤中的miR-146a表达水平增加(p = 0.01)。在原发性肿瘤中的miR-146a表达与血清癌抗原125(r = - 。0.37; p = 0.03)之间证明了负相关性和恶性算法索引的风险(r = -0.79; p = 0.0007)。总生存率与原发性肿瘤组织样品中的miR-146a表达正相关(r = 0.38; p = 0.01)。在原发性肿瘤组织的低miR-146a表达水平(危险比= 0.21; p = 0.003)中,患者存活概率减少。原发性肿瘤组织样品中的较低水平的miR-146a与较短的无进展存活(p = 0.04)和转移的铂电阻(p = 0.006)。总之,miR-146a可以是浆液性卵巢癌的预后标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号